<DOC>
	<DOC>NCT01411449</DOC>
	<brief_summary>This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Primovist for contrast enhancement in MRI of liver. The objective of this study is to assess safety, especially in relation to renal dysfunction, and efficacy of using Primovist in clinical practice. A total 2,000 patients for diagnosis on detection and identify hepatic tumor will be recruited and followed 7 days after the injection.</brief_summary>
	<brief_title>Primovist Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<criteria>Patients who received Primovist for liver MRI Patients who are contraindicated based on the product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primovist</keyword>
	<keyword>MRI agent</keyword>
</DOC>